Celcuity Inc.
Developing targeted PI3K/mTOR inhibitor therapies for breast and prostate solid tumors.
CELC | NDAQ
Overview
Corporate Details
- ISIN(s):
- US15102K1007
- LEI:
- Country:
- United States of America
- Address:
- 16305 36TH AVENUE N, 55446 MINNEAPOLIS
- Website:
- https://www.celcuity.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for various solid tumor indications. The company's lead product candidate is gedatolisib, a potential first-in-class, pan-PI3K and dual mTORC1/2 inhibitor. This therapy is designed to comprehensively blockade the PI3K/AKT/mTOR (PAM) pathway, a critical cellular pathway involved in cancer growth. Celcuity's pipeline is centered on advancing treatments for solid tumors, with a primary focus on breast and prostate cancers.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Celcuity Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Celcuity Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Celcuity Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
